Vaginal Laser Therapy: Promise vs Proof
SaveVaginal laser therapy uses heat to remodel the vaginal wall and is marketed for menopausal dryness, but sham-controlled research has not shown it beats a placebo procedure. Professional societies call the evidence insufficient, and the devices are not FDA-cleared for this use. Moisturizers, lubricants, and vaginal estrogen remain the better-proven options.
Last updated: July 2026
What is vaginal laser therapy?
Vaginal laser therapy uses fractional CO2 or Er:YAG energy to create tiny thermal injuries in the vaginal wall, with the aim of stimulating collagen and thicker tissue. Marketed under brand names such as MonaLisa Touch, it is promoted for dryness, irritation, and painful sex linked to the genitourinary syndrome of menopause (GSM) 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.Position statement concluding that evidence for energy-based (laser) devices is insufficient to recommend them for the genitourinary syndrome of menopause outside of research, and noting regulatory caution; positions moisturizers, lubricants, vaginal estrogen, DHEA, and ospemifene as evidence-based care.. Treatment is typically sold as a series of about 3 sessions spaced 4 to 6 weeks apart, plus periodic touch-ups, usually paid out of pocket.
The appeal is understandable: a hormone-free, quick in-office option. The Menopause Society acknowledges the interest while cautioning that enthusiasm has outpaced the evidence 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.Position statement concluding that evidence for energy-based (laser) devices is insufficient to recommend them for the genitourinary syndrome of menopause outside of research, and noting regulatory caution; positions moisturizers, lubricants, vaginal estrogen, DHEA, and ospemifene as evidence-based care.. Understanding what the device actually does helps put the marketing claims in context.
Does the evidence show vaginal laser works?
Early studies of vaginal laser were mostly small and uncontrolled, and they reported symptom improvement without a comparison group 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.Position statement concluding that evidence for energy-based (laser) devices is insufficient to recommend them for the genitourinary syndrome of menopause outside of research, and noting regulatory caution; positions moisturizers, lubricants, vaginal estrogen, DHEA, and ospemifene as evidence-based care.. When researchers added a sham (placebo) procedure, where the device is applied without active energy, the better-designed trials generally found no meaningful advantage of laser over the sham. Improvement in the sham groups suggests much of the early benefit reflected placebo response and natural variation.
Because of this, professional societies conclude the evidence is insufficient to recommend vaginal laser for GSM outside of clinical trials 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.Position statement concluding that evidence for energy-based (laser) devices is insufficient to recommend them for the genitourinary syndrome of menopause outside of research, and noting regulatory caution; positions moisturizers, lubricants, vaginal estrogen, DHEA, and ospemifene as evidence-based care.. The contrast with well-studied treatments is stark, since pooled randomized trials show vaginal estrogen relieves atrophy more than placebo 2Ref 2Lethaby A, Ayeleke RO, Roberts H (2016).Local oestrogen for vaginal atrophy in postmenopausal women.Systematic review of randomized trials finding low-dose local (vaginal) estrogen relieves vaginal atrophy symptoms more than placebo, an evidence base laser lacks.. A comparison group is what separates a real treatment effect from hope and time 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.Position statement concluding that evidence for energy-based (laser) devices is insufficient to recommend them for the genitourinary syndrome of menopause outside of research, and noting regulatory caution; positions moisturizers, lubricants, vaginal estrogen, DHEA, and ospemifene as evidence-based care..
Is vaginal laser safe and FDA-approved?
Vaginal laser devices are not cleared by the U.S. Food and Drug Administration to treat menopausal vaginal symptoms; their clearances cover general gynecologic surgical uses instead 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.Position statement concluding that evidence for energy-based (laser) devices is insufficient to recommend them for the genitourinary syndrome of menopause outside of research, and noting regulatory caution; positions moisturizers, lubricants, vaginal estrogen, DHEA, and ospemifene as evidence-based care.. Regulators have warned that marketing the devices for vaginal rejuvenation or menopause symptoms is unsupported, and they have noted reports of harm such as burning, scarring, and lasting pain 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.Position statement concluding that evidence for energy-based (laser) devices is insufficient to recommend them for the genitourinary syndrome of menopause outside of research, and noting regulatory caution; positions moisturizers, lubricants, vaginal estrogen, DHEA, and ospemifene as evidence-based care..
Serious complications appear uncommon, but without solid trial evidence the true balance of benefit and risk stays unclear. Similar energy devices are also promoted for postpartum changes and perimenopausal laxity, where the evidence is likewise thin 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.Position statement concluding that evidence for energy-based (laser) devices is insufficient to recommend them for the genitourinary syndrome of menopause outside of research, and noting regulatory caution; positions moisturizers, lubricants, vaginal estrogen, DHEA, and ospemifene as evidence-based care.. Anyone considering a procedure deserves a clear account of what is known and what is not 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.Position statement concluding that evidence for energy-based (laser) devices is insufficient to recommend them for the genitourinary syndrome of menopause outside of research, and noting regulatory caution; positions moisturizers, lubricants, vaginal estrogen, DHEA, and ospemifene as evidence-based care.. Cost and time are worth weighing against how uncertain the benefit remains.
What works better for vaginal dryness?
Proven options relieve the same symptoms with far more evidence. Non-hormonal moisturizers and lubricants are effective first steps for milder dryness, used every 2 to 3 days for comfort and at the time of sex 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.Position statement concluding that evidence for energy-based (laser) devices is insufficient to recommend them for the genitourinary syndrome of menopause outside of research, and noting regulatory caution; positions moisturizers, lubricants, vaginal estrogen, DHEA, and ospemifene as evidence-based care.. For moderate to severe GSM, low-dose vaginal estrogen restores the tissue and outperforms placebo in pooled trials, making it the best-supported treatment for vaginal dryness after menopause 2Ref 2Lethaby A, Ayeleke RO, Roberts H (2016).Local oestrogen for vaginal atrophy in postmenopausal women.Systematic review of randomized trials finding low-dose local (vaginal) estrogen relieves vaginal atrophy symptoms more than placebo, an evidence base laser lacks..
Other evidence-based prescriptions include vaginal DHEA and oral ospemifene 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.Position statement concluding that evidence for energy-based (laser) devices is insufficient to recommend them for the genitourinary syndrome of menopause outside of research, and noting regulatory caution; positions moisturizers, lubricants, vaginal estrogen, DHEA, and ospemifene as evidence-based care.. For whole-body symptoms, systemic hormone therapy is a separate conversation. If dryness or painful sex after menopause persists, these come before laser in current guidelines, and MedlinePlus lists vaginal estrogen among standard menopause treatments 3Ref 3MedlinePlus (National Library of Medicine) (2026).Hormone Replacement Therapy.Patient-facing overview listing vaginal estrogen among standard treatments for the genitourinary symptoms of menopause..
When laser therapy questions need a menopause clinician
A menopause-focused clinician can walk through proven options before you spend on an unproven one. Bringing up what you have tried, your goals, and your budget helps compare a laser series against moisturizers, lubricants, and vaginal estrogen honestly 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.Position statement concluding that evidence for energy-based (laser) devices is insufficient to recommend them for the genitourinary syndrome of menopause outside of research, and noting regulatory caution; positions moisturizers, lubricants, vaginal estrogen, DHEA, and ospemifene as evidence-based care.. If you are still considering laser, asking about sham-controlled trial results and whether it is offered within a study is reasonable.
Menopause typically occurs between ages 45 and 55 4Ref 4World Health Organization (2024).Menopause (fact sheet).States that menopause typically occurs between the ages of 45 and 55, framing the life stage over which these decisions are made., so these decisions often span 5 to 10 years or more, enough time to favor treatments with durable evidence. Gale can help you prepare for that conversation. Choosing evidence-backed care first rarely closes the door on other options later. The strongest evidence still points to simpler, better-studied treatments first.
Common questions
Related
Menopause & midlife
Vaginal Estrogen: When You'll Notice ChangeMenopause & midlife
Vaginal Estrogen After Breast Cancer: The EvidenceMenopause & midlife
GSM Doesn't Fade on Its Own: Why Treatment Matters
Say it back
How would you explain this to someone you love?
Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.
Before choosing an energy-based treatment
- —New or worsening pain, burning, or scarring after a laser procedure is a reason to seek clinician review
- —Any vaginal bleeding after menopause is a reason to seek evaluation rather than assuming it is from a procedure
- —Being offered laser without a discussion of proven options is a reason to seek a second opinion
- —Symptoms that persist despite treatment are a reason to ask a menopause-focused clinician about next steps
This article is general health education, not medical advice. Whether any treatment fits you depends on your health history and should be decided with a gynecologist or menopause-focused clinician.
References
- 1.The North American Menopause Society (Menopause Society) (2020). The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. doi:10.1097/GME.0000000000001609 ✓Position statement concluding that evidence for energy-based (laser) devices is insufficient to recommend them for the genitourinary syndrome of menopause outside of research, and noting regulatory caution; positions moisturizers, lubricants, vaginal estrogen, DHEA, and ospemifene as evidence-based care.
- 2.Lethaby A, Ayeleke RO, Roberts H (2016). Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD001500.pub3 ✓Systematic review of randomized trials finding low-dose local (vaginal) estrogen relieves vaginal atrophy symptoms more than placebo, an evidence base laser lacks.
- 3.MedlinePlus (National Library of Medicine) (2026). Hormone Replacement Therapy. MedlinePlus, U.S. National Library of Medicine (NIH). link ✓Patient-facing overview listing vaginal estrogen among standard treatments for the genitourinary symptoms of menopause.
- 4.World Health Organization (2024). Menopause (fact sheet). World Health Organization (WHO). link ✓States that menopause typically occurs between the ages of 45 and 55, framing the life stage over which these decisions are made.
4 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy